Status:

ACTIVE_NOT_RECRUITING

Radiation Therapy to Treat Musculoskeletal Tumors

Lead Sponsor:

St. Jude Children's Research Hospital

Collaborating Sponsors:

Lance Armstrong Foundation

Conditions:

Sarcoma, Ewing's

Rhabdomyosarcoma

Eligibility:

All Genders

Up to 25 years

Phase:

PHASE2

Brief Summary

Researchers at St. Jude Children's Research Hospital are looking for more effective ways to deliver radiation therapy to pediatric tumors of the bone and soft tissues. The goal of the study is to impr...

Detailed Description

The study focuses on the following primary Objectives: * To estimate local control rates with image guided radiation therapy as defined in this study for patients with primary musculoskeletal tumors ...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Age less than or equal to 25 years (new enrollments only). No age limit on participants who reconsent or reenroll.
  • Musculoskeletal tumor involving the primary site of origin requiring definitive, pre-operative or post-operative irradiation to that primary site.
  • No prior therapeutic irradiation at the primary site except for emergent radiation to the primary site lasting 1 week or less (5 treatment days) that can be dosimetrically accounted for in the analysis.
  • Negative serum or urine beta-HCG for females of child bearing age.
  • Patients will be stratified into 2 groups for evaluation of secondary objective endpoints based on the absence or presence of metastatic disease.
  • Patients may enter this study in specific clinical situations often defined by multimodality protocols that include the use of radiation therapy, including irradiation alone or combined with surgery (following surgical resection that may be macroscopically complete or incomplete, with positive or negative histologic margins) and/or chemotherapy (following neoadjuvant chemotherapy or combined with post-irradiation adjuvant chemotherapy).Patients requiring regional nodal irradiation and/or metastatic site irradiation are allowed as long as the primary site requires radiation.Patients with recurrent tumors or second malignant neoplasms are allowed on this study if the current primary tumor site requiring irradiation has not previously been irradiated. The treatment plan detailed in this study will allow most patients to be concurrently enrolled on institutional and COG studies.
  • Patients enrolled prior to amendment 4.0, who are still in active participation will be reconsented to the current version of the protocol (5.0).

Exclusion

    Key Trial Info

    Start Date :

    January 10 2003

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    October 1 2029

    Estimated Enrollment :

    202 Patients enrolled

    Trial Details

    Trial ID

    NCT00186992

    Start Date

    January 10 2003

    End Date

    October 1 2029

    Last Update

    March 6 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    St. Jude Children's Research Hospital

    Memphis, Tennessee, United States, 38105